Rhythm Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RYTM and other ETFs, options, and stocks.

About RYTM

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases.

CEO

David P. Meeker

CEODavid P. Meeker

Employees

414

Employees414

Headquarters

Boston, Massachusetts

HeadquartersBoston, Massachusetts

Founded

2008

Founded2008

Employees

414

Employees414

RYTM Key Statistics

Market cap

6.39B

Market cap6.39B

Price-Earnings ratio

-30.08

Price-Earnings ratio-30.08

Dividend yield

—

Dividend yield—

Average volume

924.98K

Average volume924.98K

High today

$94.13

High today$94.13

Low today

$89.52

Low today$89.52

Open price

$90.73

Open price$90.73

Volume

626.15K

Volume626.15K

52 Week high

$122.20

52 Week high$122.20

52 Week low

$45.91

52 Week low$45.91

Stock Snapshot

The current Rhythm Pharmaceuticals(RYTM) stock price is $93.52, with a market capitalization of 6.39B. The stock trades at a price-to-earnings (P/E) ratio of -30.08.

During the trading session on 2026-03-06, Rhythm Pharmaceuticals(RYTM) shares reached a daily high of $94.13 and a low of $89.52. At a current price of $93.52, the stock is +4.5% higher than the low and still -0.6% under the high.

Trading activity shows a volume of 626.15K, compared to an average daily volume of 924.98K.

The stock's 52-week range extends from a low of $45.91 to a high of $122.20.

RYTM News

TipRanks 3h

Top Rhythm Pharma Insider Executes Significant Stock Sale Move

New insider activity at Rhythm Pharmaceuticals ( (RYTM) ) has taken place on March 6, 2026. Corporate Controller and Chief Accounting Officer Christopher Paul...

Simply Wall St 2d

Rhythm Pharmaceuticals Is Down 8.2% After Positive TRANSCEND Data And FDA sNDA Progress

Rhythm Pharmaceuticals recently reported additional positive 52-week data from its global Phase 3 TRANSCEND trial of setmelanotide in acquired hypothalamic obes...

Investor's Business Daily 5d

Why Aardvark Therapeutics Just Lost More Than Half Its Value

Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win 12/11/2025 Rhythm Pharmaceuticals said Thursday said it would send it would send its leading drug...

Analyst ratings

94%

of 16 ratings

Buy

93.8%

Hold

6.3%

Sell

People also own

Based on the portfolios of people who own RYTM. This list is generated using Robinhood data, and it’s not a recommendation.

AMD

Taiwan Semiconductor Manu…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.